Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma

被引：0
|
作者：
Landgren, Ola
Alsina, Melissa
Biran, Noa
Vesole, David H.
Wallace, Paul K.
Fang, Belle
Arnold, Gregory
Kimball, Amy
Siegel, David S.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-133803
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
    Alsina, Melissa
    Landgren, Ola
    Raje, Noopur
    Niesvizky, Ruben
    Bensinger, William I.
    Berdeja, Jesus G.
    Kovacsovics, Tibor
    Vesole, David H.
    Fang, Belle
    Kimball, Amy S.
    Siegel, David S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (02) : 226 - 233
  • [2] A Phase 1b Study Investigating Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma
    Biran, Noa
    Siegel, David S.
    Berdeja, Jesus G.
    Faber, Edward
    Seneviratne, Lasika
    Alsina, Melissa
    Bensinger, William
    Kimball, Amy S.
    Zhou, Kefei
    Landgren, Ola
    BLOOD, 2016, 128 (22)
  • [3] Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
    Biran, Noa
    Siegel, David
    Berdeja, Jesus G.
    Raje, Noopur
    Cornell, Robert Frank
    Alsina, Melissa
    Kovacsovics, Tibor
    Fang, Belle
    Kimball, Amy S.
    Landgren, Ola
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (07) : 794 - 802
  • [4] A phase 1b study of once-weekly carfilzomib combined with lenalido-mide and dexamethasone (wKRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM)
    Alsina, Melissa
    Landgren, C. Ola
    Raje, Noopur
    Niesvizky, Ruben
    Bensinger, William I.
    Berdeja, Jesus
    Kovacsovics, Tibor
    Vesole, David
    Fang, Belle
    Kimball, Amy
    Siegel, David S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E52 - E52
  • [5] Weekly carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed or refractory multiple myeloma (RRMM): A phase 1b study.
    Biran, Noa
    Siegel, David Samuel DiCapua
    Berdeja, Jesus G.
    Raje, Noopur S.
    Cornell, Robert F.
    Alsina, Melissa
    Kovacsovics, Tibor
    Fang, Belle
    Kimball, Amy
    Landgren, Carl Ola
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma
    Berenson, James R.
    Cartmell, Alan
    Bessudo, Alberto
    Lyons, Roger M.
    Harb, Wael
    Tzachanis, Dimitrios
    Agajanian, Richy
    Boccia, Ralph
    Coleman, Morton
    Moss, Robert A.
    Rifkin, Robert M.
    Patel, Priti
    Dixon, Sandra
    Ou, Ying
    Anderl, Janet
    Aggarwal, Sanjay
    Berdeja, Jesus G.
    BLOOD, 2016, 127 (26) : 3360 - 3368
  • [7] Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/Relapsed or Refractory Multiple Myeloma
    Leleu, Xavier
    Beksac, Meral
    Mateos, Maria-Victoria
    Pour, Ludek
    Weisel, Katja
    Coriu, Daniel
    Obreja, Mihaela
    Goldrick, Amanda
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E266 - E267
  • [8] Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/Relapsed or Refractory Multiple Myeloma
    Leleu, Xavier
    Beksac, Meral
    Mateos, Maria-Victoria
    Pour, Ludk
    Weisel, Katja
    Coriu, Daniel
    Obreja, Mihaela
    Goldrick, Amanda
    Dimopoulos, Meletios A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S16 - S16
  • [9] An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study)
    Abe, Yu
    Kubonishi, Shiro
    Ri, Masaki
    Iino, Masaki
    Sunami, Kazutaka
    Ito, Tomoki
    Fukaya, Masafumi
    Kitano, Toshiyuki
    Ikeda, Sho
    Ota, Shuichi
    Kuroi, Taiga
    Iriyama, Noriyoshi
    Jo, Tatsuro
    Adachi, Masaaki
    Akahane, Daigo
    Kai, Tatsuyuki
    Kohara, Yoichi
    Kadowaki, Norimitsu
    Katayama, Teruaki
    FUTURE ONCOLOGY, 2024, 20 (17) : 1191 - 1205
  • [10] A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
    O'Donnell, Elizabeth K.
    Mo, Clifton C.
    Yee, Andrew J.
    Nadeem, Omar
    Branagan, Andrew R.
    Laubach, Jacob P.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette
    Harrington, Cynthia C.
    Agyemang, Emerentia
    Spillane, Kerry
    LaStofka, Brenton
    Rosenblatt, Jacalyn
    Raje, Noopur S.
    Richardson, Paul G.
    BLOOD, 2021, 138
12345